

Robert M. LORENCE et al  
Appl. No. 08/260,536  
January 4, 2006

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-331 (canceled)

332. (currently amended) A method of treating cancer in a mammal having a tumor comprising administering intravenously to said mammal more than one dose of a pharmaceutical composition comprising live purified Newcastle Disease Virus in an amount sufficient to cause tumor regression.

333. (currently amended) A method as in The method of claim 332, wherein said tumor is selected from the group consisting of: lung carcinoma, breast carcinoma, prostate carcinoma, colon adenocarcinoma, cervical carcinoma, endometrial carcinoma, ovarian carcinoma, bladder carcinoma, Wilm's tumor, fibrosarcoma, osteosarcoma, melanoma, synovial sarcoma, neuroblastoma and glioblastoma.

334. (currently amended) A method as in The method of claim 332, wherein said tumor is a colon adenocarcinoma.

335. (currently amended) A method as in The method of claim 332, wherein said tumor is a melanoma.

Robert M. LORENCE et al  
Appl. No. 08/260,536  
January 4, 2006

336. (currently amended) A method as in The method of claim 332, wherein said tumor is a neuroblastoma.

337. (currently amended) A method as in The method of claim 332, wherein said live purified Newcastle Disease Virus is strain Mass MK107.

338. (currently amended) A method as in The method of claim 332, wherein said live purified Newcastle Disease Virus is strain 73-T.

339-341. (canceled)

342. (currently amended) A method as in The method of claim 332, wherein the amount of live purified Newcastle Disease Virus administered intravenously is about  $4 \times 10^{10}$  to  $4 \times 10^{12}$  PFU/kg.

343-351. (canceled)

352. (currently amended) A method as in The method of claim 332, wherein the live purified Newcastle Disease Virus is administered intravenously in an amount of about  $10^8$  PFU.

353-366 (canceled)

Robert M. LORENCE et al  
Appl. No. 08/260,536  
January 4, 2006

367. (currently amended) A method according to The method of claim 332,  
further comprising administering a chemotherapeutic agent.

~~368. (currently amended) A method as in The method of claim 367, where  
wherein the chemotherapeutic agent is selected from the group consisting of thiotepa,  
busulfan, cyclophosphamide, methotrexate, cytarabine, bleomycin, cisplatin,  
doxorubicin, melphalan, mercaptopurine, vinblastine, 5-fluorouracil, taxol paclitaxel, and  
retinoic acid.~~

369. (currently amended) ~~A method as in The method of claim 368, where~~  
wherein the chemotherapeutic agent is 5-fluorouracil.

370. (currently amended) A method according to The method of claim 332,  
further comprising administering an immunosuppressive agent.

371. (currently amended) ~~A method as in The method of claim 370,~~ wherein said immuno-suppressive agent is a corticosteroid.

372. (currently amended) A method according to The method of claim 332,  
further comprising administering a cytotoxic or cytostatic agent.

373. (currently amended) A method as in The method of claim 372, wherein said cytotoxic or cytostatic agent is an antibody.

Robert M. LORENCE et al  
Appl. No. 08/260,536  
January 4, 2006

374. (currently amended) A method as in The method of claim 372, wherein said cytotoxic or cytostatic agent is a cytokine.

375-385. (canceled)

386. (currently amended) A method according to The method of claims 332, wherein said live purified Newcastle Disease Virus is purified from cell culture.

387. (currently amended) A method as in The method of claim 332, wherein said tumor is cervical carcinoma.

388-391. (canceled)

392. (currently amended) A method according to The method of claim 332, wherein said pharmaceutical composition Newcastle Disease Virus is in the form of a composition which consists essentially of live purified Newcastle Disease Virus.

393. (currently amended) A method according to The method of claim 332, wherein said Newcastle Disease Virus is in the form of a pharmaceutical composition also comprising comprises a pharmaceutically acceptable carrier.

Robert M. LORENCE et al  
Appl. No. 08/260,536  
January 4, 2006

394. (currently amended) A method according to The method of claim 332,  
wherein said tumor is a human tumor.

395. (currently amended) A method according to The method of claim 332,  
wherein said tumor is greater than 0.6 cm in diameter.

396. (currently amended) A method according to The method of claim 332,  
wherein said tumor is a metastatic tumor.

397. (currently amended) A method according to The method of claim 332,  
wherein said amount administered is sufficient to cause complete tumor regression.

398. (canceled)

399. (currently amended) A method according to The method of claim 332,  
further comprising administering radiation.

400-402. (canceled).

403. (currently amended) A method according to The method of claims 332,  
wherein said administering step causes method results in tumor regression.